The short version of peptide hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Trials for cardiovascular health === In March 2024, the US Food and Drug Administration expanded the indication for semaglutide (brand name Wegovy) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and who are either obese or overweight. This was based on a placebo-controlled randomized double-blind trial, which was sponsored by Novo Nordisk, on the efficacy and safety of semaglutide for this indication. 17,604 participant were randomly assigned to receive either semaglutide (Wegovy) or placebo. Participants in both groups also received standard-of-care medical treatment (e.g., management of blood pressure and cholesterol) and healthy lifestyle counseling (including diet and physical activity). The trial reported cumulative occurrence of major adverse cardiovascular events, a primary end-point event of the trial, for 569 of the 8803 patients in the semaglutide group, which were 6.5% of the participants, and for 701 of the 8801 patients in the placebo group, which were 8% of the participants, showing relative 18.8% less major adverse cardiovascular events, such as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurring for participants who had received semaglutide in the trial relative to those who had received placebo over the course of around 48 months, or 34.2±13.7 months, which was the mean (±SD) total duration of the participants in either group's exposure to the placebo or semaglutide during the trial.
== External links == Examination of Leonardo da Vinci's Madonna of the Yarnwinder using PIXE[link removed] Application of PIXE to the study of Renaissance style enameled gold jewelry (PDF) PDI-PIXE-MS: Particle Desorption Ionization Particle-Induced X-Ray Emission Mass Spectrometry (PDF) PIXEMS PNNL031209 – Pacific Northwest National Laboratory Presentation – "Particle Desorption Ionization Particle-Induced X-Ray Emission Mass Spectrometry" – PDI-PIXE-MS. (PDF) Sproch, N., Ashbaugh, M.D., Morse, D., Grant, P., McIntyre Jr., L.C., Antolak, A., Fernando, Q., "PD/PIXE-MS: Particle Desorption Particle Induced X-ray Emission Mass Spectrometry", Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics; Chicago, Il, May 27 – May 31, 2001.
The oxygen transmission rate of a gas through packaging is defined as the amount of oxygen permeating per unit of permeable area and per unit of time in a packaging system considering standardized test conditions (23 °C and 1 atm. partial pressure difference). It is an effective tool to estimate the barrier properties of a certain material. The determination of the OTR is usually carried out by means of a steady-state and isostatic method, reported by the ASTM D 3985 or ASTM F 1307, containing respectively standardized protocols for the measurements of the OTR of several kinds of packaging. The typical instrumentation consists in a permeation cell composed by two distinct chambers, separated by the tested material; one of the chambers is then filled with a carrier gas (e.g., nitrogen), while the other one with oxygen, hence creating the necessary driving force to let the oxygen permeate across the barrier's material.
== The "no waste" culture == Sake kasu can be considered as a part of the "no waste" culture in Japan. Sake kasu is the waste produced by sake production, and the Japanese decided to use it because they do not want to waste any of the ingredients. A lot of sake kasu is produced during sake production and a lot of sake kasu is considered as industrial waste and being discarded. In order to reduce the waste produced by the sake kasu in Japan, it is recycled for use in other products. Some breweries sell their sake kasu directly to restaurants or put it into packages sold in convenient stores and supermarkets.
Sources: en.wikipedia.org
primase Any of a class of enzymes that catalyze the synthesis of short, ~10-base RNA oligonucleotides, which by complementing the lagging strand during DNA replication are used as primers by DNA polymerase to initiate the synthesis of Okazaki fragments.
In many MHD systems, most of the electric current is compressed into thin, nearly two-dimensional ribbons termed current sheets. These can divide the fluid into magnetic domains within which the currents are relatively weak. Current sheets in the solar corona are thought to be between a few meters and a few kilometers thick, which is quite thin compared to the magnetic domains, which are thousands to hundreds of thousands of kilometers across. Another example occurs in the Earth's magnetosphere, where current sheets separate topologically distinct domains, isolating most of the Earth's ionosphere from the solar wind.
With the encouragement of Ollendorff (promising that a US organization called "The Friends of the Technion" would support Feher's studies), he applied for 50 universities in the US, and only two were willing to accept him. He could not afford the voyage to US so he started a small production line for devices with piezoelectric crystals, mainly microphones. In December 1946 he arrived to New York, where he realized that "Friends of the Technion" would not fund his degree. With poor means he attended the University of California, Berkeley, where he received his bachelor's degree in engineering physics (1950), master's degree in electrical engineering (1951) and doctorate (1954).
Chromatography is a 2004 post trip-hop album by Second Person. This is the band's debut album and all songs were written by Julia Johnson and Mark Maclaine, except "Word for Word" which also credits Ed Webber and Tristan Kajanus, "Demons Die" which also credits Álvaro López and "Divine" which was written by Julia Johnson. The album was recorded, produced and mixed by Mark Maclaine (aka The Silence) at The Silence Corporation Studios, London. The songs "I Spy" and "My Baby Only Cares For Me" were originally written for the 2003 ski/snowboard film: Snow's in the House 2 and they can be found as earlier incarnations on the film's soundtrack.
The varied geography and climatology of Italy has led to many cases of spontaneous mummification. Italian mummies display the same diversity, with a conglomeration of natural and intentional mummification spread across many centuries and cultures. The oldest natural mummy in Europe was discovered in 1991 in the Ötztal Alps on the Austrian-Italian border. Nicknamed Ötzi, the mummy is a 5,300-year-old male believed to be a member of the Tamins-Carasso-Isera cultural group of South Tyrol. Despite his age, a recent DNA study conducted by Walther Parson of Innsbruck Medical University revealed Ötzi has 19 living genetic relatives. The Capuchin Catacombs of Palermo were built in the 16th century by the friars of Palermo's Capuchin monastery. Originally intended to hold the deliberately mummified remains of dead friars, interment in the catacombs became a status symbol for the local population in the following centuries. Burials continued until the 1920s, with one of the final burials being that of Rosalia Lombardo. In all, the catacombs host nearly 8000 mummies. The most recent discovery of mummies in Italy came in 2010, when sixty mummified human remains were found in the crypt of the Conversion of St Paul church in Roccapelago di Pievepelago, Italy. Built in the 15th century as a cannon hold and later converted in the 16th century, the crypt had been sealed once it had reached capacity, leaving the bodies to be protected and preserved. The crypt was reopened during restoration work on the church, revealing the diverse array of mummies inside.
Sources: en.wikipedia.org
In October 2023, Newsom vetoed several bills aimed at expanding access to housing assistance including the California Social Housing Act. One was a bill to repurpose unused state-owned land for affordable housing, which he said infringed on state sovereignty. Another would have expanded the number of people who qualify for state housing assistance. A third would have mandated that Medi-Cal cover the cost of housing assistance. Newsom has signed the Abundant and Affordable Homes Near Transit Act, Affordable Housing on Faith and Higher Education Lands Act, California Assembly Bill 2097 (2022) and California HOME Act. In August 2024, Newsom warned counties that did not remove their homeless encampments that failure to do so would result in their state funding being cut off the next year. He issued this warning after personally visiting and clearing out a Los Angeles homeless encampment without notifying the city beforehand. In September 2024, Newsom vetoed Assembly Bill 1840, which sought to prohibit the disqualification of applicants to California Housing Finance Agency home purchase assistance programs based solely on their immigration status.
== In proteins == In proteins, a structural motif describes the connectivity between secondary structural elements. An individual motif usually consists of only a few elements, e.g., the 'helix-turn-helix' motif which has just three. Note that, while the spatial sequence of elements may be identical in all instances of a motif, they may be encoded in any order within the underlying gene. In addition to secondary structural elements, protein structural motifs often include loops of variable length and unspecified structure. Structural motifs may also appear as tandem repeats.
== Biological applications == Chemiluminescence has been applied by forensic scientists to solve crimes. In this case, they use luminol and hydrogen peroxide. The iron from the blood acts as a catalyst and reacts with the luminol and hydrogen peroxide to produce blue light for about 30 seconds. Because only a small amount of iron is required for chemiluminescence, trace amounts of blood are sufficient. In biomedical research, the protein that gives fireflies their glow and its co-factor, luciferin, are used to produce red light through the consumption of adenosine triphosphate (ATP). This reaction is used in many applications, including the effectiveness of cancer drugs that choke off a tumor's blood supply. This form of bioluminescence imaging allows scientists to test drugs in the pre-clinical stages cheaply. Another protein, aequorin, found in certain jellyfish, produces blue light in the presence of calcium. It can be used in molecular biology to assess calcium levels in cells. What these biological reactions have in common is their use of ATP as an energy source. Though the structure of the molecules that produce luminescence is different for each species, they are given the generic name of luciferin. Firefly luciferin can be oxidized to produce an excited complex. Once it falls back down to a ground state a photon is released. It is very similar to the reaction with luminol.
A hibernation factor is a protein used by cells to induce a dormant state by slowing or halting the cellular metabolism. This can occur during periods of stress, randomly in order to allocate "designated survivors" in a population, or when bacteria cease growth (enter stationary phase). Hibernation factors can do a variety of things, including dismantling cellular machinery and halting gene expression, but the most important hibernation factors bind to the ribosome and halt protein production, which consumes a large fraction of the energy in a cell.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.